Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT03712566 Not yet recruiting - Cancer Clinical Trials

Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy

Start date: October 2018
Study type: Observational

This is prospective research study which will include patients with recurrent or metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal starting on first-line platinum based chemotherapy or any line of immunotherapy treatment.This study aims to characterize the dynamic changes in genomic, epigenetic, immune profiling and imaging data during treatment with systemic therapy. Patients will have archived tumor samples requested as well as blood samples collected at up to four time points to analyze these changes. Imaging data will be derived from patients' routine CT scans before and after treatment.

NCT ID: NCT03712436 Not yet recruiting - Cancer Clinical Trials

Examining Early Palliative Care in Newly Diagnosed Cancer Patients

Start date: November 30, 2018
Phase: N/A
Study type: Interventional

To understand the impact of initiation of palliative care in this low-resource setting, and whether palliative care is a cost-reducing intervention that will improve patient-reported outcomes and quality of life.

NCT ID: NCT03708224 Not yet recruiting - Cancer Clinical Trials

Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma

Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

To determine the effect of neoadjuvant atezolizumab alone or in combination with emactuzumab, CPI-444, and other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.

NCT ID: NCT03707301 Not yet recruiting - Cancer Clinical Trials

Post-SOPHrology Cancer Patients' anxieTY Report

Start date: October 20, 2018
Study type: Observational

Cancer is pathology with a high impact on patients and relatives quality of life. Most of the time, it is a stressful trial. Professionals have often resort to pharmaceutical solutions, but sometimes, it is not sufficient. So, patients resort to alternative and complementary medicines, as sophrology. In Lucien Neuwirth Cancer Institute, patients can benefit from sophrology. Anxiety levels have never been reported before and after sessions. Indeed, the present study wants to report anxiety levels before, after, and one and three weeks after session. Levels of satisfaction will also be reported.

NCT ID: NCT03705052 Completed - Cancer Clinical Trials

Patient's and Caregiver's Expectations and Preferences Concerning Art Therapy Activities for Cancer Support

Start date: May 22, 2018
Phase: N/A
Study type: Interventional

Cancer patients and their caregivers often experience difficulties in coping with the cancer diagnosis and the treatment that follows. Creative art therapy could support cancer patients and their caregivers in coping with these issues by using their creativity and self-expression. The aim of this study for the investigator's research team is to create a clear image of what cancer patients and their caregivers expect of supportive care to help them coping with cancer diagnosis, cancer therapy and life after cancer. This is a prospective, interventional study. Cancer patients and their caregivers will be approached to participate in this study. They will be asked to complete a questionnaire about their satisfaction with the current support they get to help them coping with cancer diagnosis, cancer therapy and life after cancer and whether they would like to participate in an art therapy program, which art therapy forms they would like to participate in, how they would like them to be organized, etc.

NCT ID: NCT03702309 Recruiting - Breast Cancer Clinical Trials

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Start date: August 3, 2017
Study type: Observational

The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.

NCT ID: NCT03699748 Recruiting - Cancer Clinical Trials

Lay Health Worker Engage, Educate, and Encourage Patients to Share

Start date: October 3, 2018
Phase: N/A
Study type: Interventional

The purpose of the LEAPS program is to understand how a trained lay health worker who engages with newly diagnosed patients after a diagnosis of an advanced stage of cancer can help to engage patients in advance care planning, improve patient satisfaction with their decision-making, activation, quality of life, and healthcare resource utilization.

NCT ID: NCT03694431 Not yet recruiting - Cancer Clinical Trials

Comparative Trial of Home-Based Palliative Care

Start date: January 2019
Phase: N/A
Study type: Interventional

Background: To effectively alleviate suffering and improve quality of life for patients with serious illness and their caregivers, palliative care (PC) services must be offered across multiple settings. Research is needed to determine how best to optimize home-based palliative care (HBPC) services to meet the needs of individuals with high symptom burden and functional limitations. Aim: The investigators will compare a standard HBPC model that includes routine home visits by a nurse and provider with a more efficient tech-supported HBPC model that promotes timely inter-professional team coordination via synchronous video consultation with the provider while the nurse is in the patient's home. The investigators hypothesize that tech-supported HBPC will be as effective as standard HBPC. Design: Cluster randomized trial. Registered nurses (n~130) will be randomly assigned to the tech-supported or standard HBPC model so that half of the patient-caregiver dyads will receive one of the two models. Setting/Participants: Kaiser Permanente (15 Southern California and Oregon sites). Patients (n=10,000) with any serious illness and a prognosis of 1-2 years and their caregivers (n=4,800) Methods: Patients and caregivers will receive standard PC services: comprehensive needs assessment and care planning, pain and symptom management, education/skills training, medication management, emotional/spiritual support; care coordination, referral to other services, and 24/7 phone assistance. Results: Primary patient outcomes: symptom improvement at 1 month and days spent at home in the last six months of life; caregiver outcome: perception of preparedness for caregiving. Conclusion: Should the more efficient tech-supported HBPC model achieves comparable improvements in outcomes that matter most to patients and caregivers, this would have a lasting impact on PC practice and policy.

NCT ID: NCT03694171 Completed - Cancer Clinical Trials

Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)

Start date: November 2013
Study type: Observational

The growing incidence of cancer associated to an aging population represents an epidemiologic reality that requires questioning access to care and prognosis in elderly with cancer, for which disparities have been highlighted. However, generally speaking, studies are limited in that they overlook geriatric-specific factors. The aim of this work was to study sociodemographic, socioeconomic and clinical determinants of access to care (cancer stage, cancer treatment) and prognosis (functional decline, survival) in elderly cancer patients.

NCT ID: NCT03693339 Recruiting - Cancer Clinical Trials

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Start date: October 30, 2018
Phase: Phase 2
Study type: Interventional

This study is a phase II, single-arm, open label study under an umbrella trial for NSCLC. This clinical study is targeted for the patients who harbor exon 14 skipping mutation of MET and all patients will be treated with Capmatinib. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.